A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

A Randomized Multicenter Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
Recruiting
18 years - 98 years
All
Phase 2
5 participants needed
1 Location

Brief description of study

The BBI-DSP-7888-201G trial is designed to compare the overall survival (OS) between treatment with DSP-7888 Dosing Emulsion plus bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following initial therapy. This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study. Approximately 200 patients will be enrolled from up to 70 investigational sites in the US, Canada, Japan, Taiwan, and South Korea.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Brain Neoplasms, Glioblastoma
  • Age: 18 years - 98 years
  • Gender: All


Updated on 16 Oct 2024. Study ID: 828092

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center